Get started
Author

Anil Veluvolu

Observed name: A. Veluvolu
Observed institution: Willis-Knighton Cancer Center
ORCID: 0009-0007-4779-8442
Observed ORCID: 0009-0007-4779-8442
OpenAlex ID: A5073345627
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · Bruno Sangro, Masatoshi Kudo, et al. · The Lancet · 389
PDF
Acinar cell carcinoma presenting as a duodenal mass: review of the literature and a case report.
2013 · Alireza Hamidian Jahromi, Hosein Shokouh-Amiri, et al. · PubMed · 12
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
2024 · Stephen Lam Chan, Bruno Sangro, et al. · Journal of Clinical Oncology · 6
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
2024 · Masatoshi Kudo, Stephen Lam Chan, et al. · Journal of Clinical Oncology · 3
PDF
Primary pancreatic squamous cell carcinoma with duodenal invasion: Literature review and a case report
2026 · Farman H. Fatah, Alana Hofmann, et al. · Radiology Case Reports
PDF
Incidental High-Grade Appendiceal Mucinous Neoplasm
2026 · Farman H. Fatah, Gazi B. Zibari, et al. · CRSLS Journal of the Society of Laparoscopic and Robotic Surgeons
Robotic Resection of Caudate Lobe Hepatocellular Carcinoma
2026 · Farman H. Fatah, Gazi B. Zibari, et al. · CRSLS Journal of the Society of Laparoscopic and Robotic Surgeons
Abstract CT018: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies
2025 · Anisha B. Patel, Ofer Purim, et al. · Cancer Research
1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma
2024 · Stephen L Chan, Masatoshi Kudo, et al. · Journal for ImmunoTherapy of Cancer
Impact of vascular resection on the surgical outcomes in patients with pancreatic tumor
2024 · H. Shokouh-Amiri, H. Patel, et al. · HPB
PDF
Impact of vascular resection on the surgical outcome in patients with pancreatic tumor
2024 · H. Shokouh-Amiri, G. Zibari, et al. · HPB
PDF
Minimally invasive versus open surgery in treatment of liver lesions
2017 · H. Shokouh-Amiri, S. Ahmadzadeh, et al. · HPB
PDF
Minimally invasive versus open surgery in treatment of distal pancreatic lesions
2017 · G. Zibari, S. Ahmadzadeh, et al. · HPB
PDF
The role of local excision in management of benign and malignant lesions of ampullary and peri-ampullary region
2016 · H. Shokouh-Amiri, S. Ahmadzadeh, et al. · HPB
PDF
Works count: 15
Citation count: 799
H-index: 4
I10-index: 3
Year
Topic
Type